An interventional study of ZhenQi FuZheng granules (ShiDaiYangGuang) in Rhinitis, Allergic, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment
ZhenQi FuZheng granules has been used to improve the immune function of human body, protect the bone marrow and adrenal cortex function and promote the recovery of positive function in traditional Chinese medicine care, especially with the immune imbalance diseases like post-surgery, chemotherapy and rhinitis. This project intends to establish AR（allergic rhinitis）specimen library, cell and animal model experiment, combining clinical cohort research with applied basic research, further assess the therapeutic mechanism of ZhenQiFuZheng granules in AR. We assume that ZhenQi FuZheng granules could cause the metabolic omics changes of nasal inflammatory factors and nasal secretions in AR patients, thus improving the type 2 inflammation level of allergic rhinitis.
1,042 studies on the registry are indexed under Rhinitis, Allergic; 91 are open to participants now.
This study's planned enrollment of 40 is below the median of 90 across 858 interventional studies indexed under Rhinitis, Allergic.
Browse Rhinitis, Allergic studies →The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 563 studies on the registry; 311 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ZhenQi FuZheng granules (ShiDaiYangGuang) 1 bag at a time, twice a day. Oral for 4 weeks.
Drug: ZhenQi FuZheng granules (ShiDaiYangGuang)
1 bag at a time, twice a day. Oral orally for 4 weeks.
Rhinoconjunctivitis Quality of Life Questionnaire
Patients were scored by questionnaire before and after treatment, and the change in score before and after treatment was the primary outcome measure
Time frame: 12 weeks
Visual Analog Score for pain
Patients were scored by questionnaire before and after treatment, and the change in score before and after treatment was the primary outcome measure
Time frame: 12 weeks
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.
Of 74 non-industry interventional studies with no phase under Rhinitis, Allergic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's planned 12 months is close to that.
Counting every sponsor, half of 94 studies reached it within 12 months; a quarter within 4 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University →